

ACCESS TO THERAPY

Poland

Robert Flisiak

Department of Infectious Diseases and Hepatology
Medical University of Białystok, Poland



10th PHC
Paris, 30-31 January 2017



Disclosures


Advisor and/or speaker for:

AbbVie, Bristol-MyersSquibb, Gilead, Janssen,
Merck, Novartis, Roche

Availability of DAA in UE vs. Poland



UE registration



Reimbursement in Poland

Therapies reimbursed in Poland by National Health Fund

in IFN-free therapeutic program


IFN-free reimbursed for all HCV infected with any stage of fibrosis (F1-F4) and for F0 if IFN-based regimen is contraindicated ...

Regimen	Genotypes						
	1a (2%)	1b (83%)	2	3 (11%)	4 (4%)	5	6
OBV/PTV/r ± DSV ± RBV	X	X					
OBV/PTV/r ± RBV					X		
ASV + DCV		X					
SOF/LDV	X	X					
SOF + Peg-IFN + RBV			X	X	X	X	X
SOF + RBV			X	X	X	X	X

OBV – ombitasvir, PTV – paritaprevir, /r/ – ritonavir, DSV – dasabuvir, RBV – ribavirin, ASV – asunaprevir, DCV – daclatasvir, SOF – sofosbuvir, LDV – ledipasvir, Peg-IFN – pegylated interferon

... but financial cap on the national and site level is still a limitation

Annual number of treated patients




total cost of HCV therapeutic program in 2016 ~400 mln PLN (~93 mln EUR)

average cost of treatment per one patient in 2016 ~65,000 PLN (~15,000 EUR)

SVR rates at the turn of the interferon era in Poland


different regimens in 5646 patients infected with HCV genotype 1,
1 January 2013 - 31 March 2016, data from 29 Polish centers

EpiTer-1 study



Elimination of HCV and HCC in Poland with different scenarios of diagnostics and treatment


HCV infection



Three scenario for 2013-2030

- 1. Basic scenario (2013):** diagnosed 3000 and treated 4000 per year, SVR=70% .
- 2. Control scenario:** diagnosed 5000 and treated 5000 per year, SVR>90%.
- 3. Elimination scenario:** diagnosed 15000 and treated 15000 pre year, SVR>90%.

HCC cases



Access to HBV treatment

- In contrast to HCV therapeutic program elastography is not approved for enrollment to HBV reimbursed therapy.
- Entecavir and Tenofovir (TDF) reimbursed for majority of treated (<200 EUR per month).
- PegIFNa2a reimbursed and still in use (700 EUR per month).
- Some patients are still on Lamivudine (30 EUR per month).
- TAF not reimbursed yet.
- Reimbursement of NUCs combination difficult to obtain.
- No reimbursement for combination of PegIFNa2a + NUC.